xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05968196</url>
    </required_header>
    <id_info>
      <org_study_id>noar99</org_study_id>
      <nct_id>NCT05968196</nct_id>
    </id_info>
    <brief_title>Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma</brief_title>
    <acronym>HCC and FTC</acronym>
    <official_title>Clinicopathological Characteristics of Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma Without Completion Thyroidectomy</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>The Catholic University of Korea</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>The Catholic University of Korea</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this retrospective study is to evaluate in patients with HCC and FTC who&#xD;
        underwent lobectomy. The main questions it aims to answer are:&#xD;
  &#xD;
          -  The necessity of completion thyroidectomy based on the clinicopathological&#xD;
             characteristics&#xD;
  &#xD;
          -  Prognosis Participants underwent thyroid lobectomy Researchers compared HCC and FTC&#xD;
             groups to see the prognosis after lobectomy.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Background The prognosis of Hürthle cell carcinoma (HCC) and follicular thyroid carcinoma&#xD;
        (FTC) is poorly understood. These types of cancers are usually confirmed after diagnostic&#xD;
        lobectomy. We aimed to evaluate the clinicopathological characteristics and prognoses of&#xD;
        patients with HCC and FTC who did not undergo completion thyroidectomy.&#xD;
  &#xD;
        Materials and Methods We screened 221 patients diagnosed with FTC or HCC after thyroid&#xD;
        lobectomy at Yonsei Severance Hospital between January 2000 and December 2020. After&#xD;
        excluding patients who underwent complete thyroidectomy, 184 patients with FTC and 37&#xD;
        patients with HCC were included.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">January 1, 2000</start_date>
    <completion_date type="Actual">March 31, 2023</completion_date>
    <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Retrospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Disease-free survival (DFS)</measure>
      <time_frame>From January 2000 to March 2023</time_frame>
      <description>a comparison of disease-free survival (DFS) between FTC and HCC groups</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>TNM stage</measure>
      <time_frame>From January 2000 to March 2023</time_frame>
      <description>a comparison of TNM stage between FTC and HCC groups</description>
    </secondary_outcome>
    <number_of_groups>2</number_of_groups>
    <enrollment type="Actual">221</enrollment>
    <condition>Huerthle Cell Carcinoma</condition>
    <arm_group>
      <arm_group_label>FTC</arm_group_label>
      <description>Follicular thyroid carcinoma</description>
    </arm_group>
    <arm_group>
      <arm_group_label>HCC</arm_group_label>
      <description>Hurthle cell carcinoma</description>
    </arm_group>
    <eligibility>
      <study_pop>
        <textblock>
          Patients in FTC and HCC who underwent thyroid lobectomy&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Follicular thyroid carcinoma&#xD;
  &#xD;
            -  Hurthle cell carcinoma&#xD;
  &#xD;
            -  Lobectomy&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Completion thyroidectomy&#xD;
  &#xD;
            -  Total thyroidectomy&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>N/A</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 12, 2023</study_first_submitted>
    <study_first_submitted_qc>July 20, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 1, 2023</study_first_posted>
    <last_update_submitted>July 20, 2023</last_update_submitted>
    <last_update_submitted_qc>July 20, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
      <investigator_full_name>Kwangsoon Kim</investigator_full_name>
      <investigator_title>Assistant Professor</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Carcinoma</mesh_term>
      <mesh_term>Thyroid Neoplasms</mesh_term>
      <mesh_term>Adenocarcinoma, Follicular</mesh_term>
      <mesh_term>Adenocarcinoma</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Undecided</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05968196
  org study id: noar99
  nct id: NCT05968196
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this retrospective study is to evaluate in patients with HCC and FTC who
        underwent lobectomy. The main questions it aims to answer are:
  
          -  The necessity of completion thyroidectomy based on the clinicopathological
             characteristics
  
          -  Prognosis Participants underwent thyroid lobectomy Researchers compared HCC and FTC
             groups to see the prognosis after lobectomy.
  Background The prognosis of Hürthle cell carcinoma (HCC) and follicular thyroid carcinoma
        (FTC) is poorly understood. These types of cancers are usually confirmed after diagnostic
        lobectomy. We aimed to evaluate the clinicopathological characteristics and prognoses of
        patients with HCC and FTC who did not undergo completion thyroidectomy.
  
        Materials and Methods We screened 221 patients diagnosed with FTC or HCC after thyroid
        lobectomy at Yonsei Severance Hospital between January 2000 and December 2020. After
        excluding patients who underwent complete thyroidectomy, 184 patients with FTC and 37
        patients with HCC were included.
  observational model: Cohort
  time perspective: Retrospective
  measure: Disease-free survival (DFS)
  time frame: From January 2000 to March 2023
  description: a comparison of disease-free survival (DFS) between FTC and HCC groups
  measure: TNM stage
  time frame: From January 2000 to March 2023
  description: a comparison of TNM stage between FTC and HCC groups
  arm group label: FTC
  description: Follicular thyroid carcinoma
  arm group label: HCC
  description: Hurthle cell carcinoma
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: N/A
  maximum age: N/A
  healthy volunteers: No
  responsible party type: Principal Investigator
  investigator affiliation: The Catholic University of Korea
  investigator full name: Kwangsoon Kim
  investigator title: Assistant Professor
  mesh term: Carcinoma
  mesh term: Thyroid Neoplasms
  mesh term: Adenocarcinoma, Follicular
  mesh term: Adenocarcinoma
  sharing ipd: Undecided